Predicting and preventing the future: Actively managing multiple sclerosis

Practical Neurology

Volumn 9, Issue 3, 2009, Pages 133-143

  Hutchinson, Michael ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; IMMUNOLOGIC FACTOR; INTERFERON BETA SERINE; INTERFERON BETA-1B;

FEMALE; FORECASTING; HUMAN; INFLAMMATION; MALE; MULTIPLE SCLEROSIS; ONSET AGE; PATHOPHYSIOLOGY; REVIEW; SEXUAL DEVELOPMENT;

AGE OF ONSET; FEMALE; FORECASTING; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SEX CHARACTERISTICS;

EID: 67650151002     PISSN: 14747758     EISSN: 14747766     Source Type: Journal    
DOI: 10.1136/jnnp.2009.177212     Document Type: Review

References (46)

1. Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-8.
2. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain2003;126:770-82.
3. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study: I. Clinical course and disability. Brain1989;112:133-46.
4. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study: II. Predictive value of the early clinical course. Brain 1989;112:1419-28.
5. Weinshenker BG, Rice GPA, Noseworthy JH, et al. The natural history of multiple sclerosis: a geographically based study: III. Multivariate analysis of predictive factors and models of outcome. Brain 1991;114:1045-56.
6. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with 25 years of follow up. Brain 1993;116:117-34.
7. Bergamaschi R, Quaglini S, Trojano M, et al. Early prediction of the long term evolution of multiple sclerosis: the Bayesian risk estimate for multiple sclerosis (BREMS) score. J Neurol Neurosurg Psychiatry 2007;78:757-9.
8. Sormani MP, Rovaris M, Comi G, et al. A composite score to predict short-term disease activity in patients with relapsing-remitting MS. Neurology2007;69:1230-5.
9. Hirst C, Ingram G, Swingler R, et al. Change in disability in patients with multiple sclerosis: a 20- year prospective population-based analysis. J Neurol Neurosurg Psychiatry 2008;79:1137-43.
10. Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 1999;67:148-52.
11. Costelloe L, Thompson A, Walsh C, et al. Long term clinical relevance of criteria for designating multiple sclerosis as benign after ten years of disease. J Neurol Neurosurg Psychiatry2008;79:1245-8.
12. Pittock SJ, McClelland RL, Mayr WT. Clinical implications of benign multiple sclerosis: A 20-year population based follow-up study. Ann Neurol2004;56:303-6.
13. Sayao AL, Devonshire V, Tremlett H. Longitudinal follow-up of ''benign'' multiple sclerosis at 20 years. Neurology 2007;68:496-500.
14. Amato MP, Portaccio E, Stromillo ML, et al. Cognitive impairment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. Neurology 2008;71:632-8.
15. Lublin FD, Baier M, Cutter GR. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528-36.
16. Hirst C, Ingram G, Pearson O, et al. Contribution of relapses to disability in multiple sclerosis. J Neurol2008;255:280-7.
17. Wilkins A, Scolding N. Protecting axons in multiple sclerosis. Mult Scler 2008;14:1013-25.
18. Tintore' M, Rovira A, RI'o J, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008;70:1079-83.
19. Jin YP, de Pedro-Cuesta J, Huang YH, et al. Predicting multiple sclerosis at optic neuritis onset. Mult Scler 2003;9:135-41.
20. Joseph FG, Hirst CL, Pickersgill T, et al. CSF oligoclonal band status informs prognosis in MS: a case control study of 100 patients. J Neurol Neurosurg Psychiatry 2008;80:292-6.
21. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain2008;131:808-17.
22. Minneboo A, Jasperse B, Barkhof F, et al. Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters. J Neurol Neurosurg Psychiatry 2008;79:917-23.
23. Mesaros S, Rocca MA, Sormani MP, et al. Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS. A large-scale, short-term follow up study. J Neurol2008;255:1378-83.
24. McFarland HF, Barkhof F, Antel J, et al. The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult Scler 2002;8:40-51.
25. Fisniku LK, Chard DT, Jackson JS, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008;64:247-54.
26. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006;253:98-108.
27. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ''McDonald Criteria''. Ann Neurol2005;58:840-6.
28. Association of British Neurologists. Guidelines for the use of betainterferons and glatiramer acetate in multiple sclerosis. 2001. Available at http://theabn. org/documents/msdoc.pdf (accessed 3 Dec 2008).
29. Riazi A, Hobart JC, Lamping DL, et al. Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples. J Neurol Neurosurg Psychiatry 2002;73:701-4.
30. Costelloe L, O'Rourke K, Kearney H, et al. The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical). J Neurol Neurosurg Psychiatry 2007;78:841-4.
31. O'Rourke KE, Hutchinson M. Stopping betainterferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005;11:46-50.
32. Rudick RA, Lee JC, Simon J, et al. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004;56:548-55.
33. Waubant E, Vukusic S, Gignoux L, et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003;61:184-9.
34. O'Rourke K, Walsh C, Antonelli G, et al. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. Mult Scler 2007;13:336-42.
35. Rio J, Nos C, Tintore M, et al. Assessment of different treatment failure criteria in a cohort of relapsing multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 2002;52:400-6.
36. Bosca I, Coret F, Valero C, et al. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon. Mult Scler 2008;14:636-9.
37. Jeffery D, Bashir K, Buchwald L, et al. Optimizing immunomodulatory therapy for MS patients: an integrated management model. J Neurol Sci2002;201:89-90.
38. Freedman MS, Patry DG, Grand'Maison F, et al. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004;31:157-68.
39. PRISMS (Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) Study Group. Randomized double-blind placebo controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet1998;352:1498-502.
40. Freedman MS, Forrestal FG. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients treated with interferon B-1a: analysis of the PRIMS study. Mult Scler 2008;14:1234-41.
41. NICE technology appraisal guidance 127. Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis. Available at http://www.nice.org.uk/TA127 (accessed 3 Dec 2008).
42. Polman CH, O'Connor PW, Havrdova E, et al. for the AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006;354:899-910.
43. The CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-801.
44. Hartung HP, Gonsette R, Konig N, et al, for the Mitoxantrone im Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet2002;360:2018-25.
45. Hauser SL, Waubant E, Arnold DL, et al, , for the HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Eng J Med 2008;358:676-88.
46. EMEA guidelines. Available at http://www.emea. europa.eu/humandocs/PDFs/ EPAR/tysabri/H-603- en6.pdf (accessed 30 Oct 2008).